fNIRS-Based Neurofeedback Training in Children With ADHD: The Effects of VR
Launched by THE UNIVERSITY OF HONG KONG · Dec 16, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new type of treatment for children aged 7 to 12 who have Attention Deficit Hyperactivity Disorder (ADHD). The researchers want to see if using a technique called neurofeedback, which helps children learn to control their brain activity, can improve their attention and focus. They are also exploring whether adding virtual reality (VR) technology makes this treatment even more effective. Children in the study will be placed into one of three groups: one group will use VR while practicing neurofeedback, another group will use a standard computer for neurofeedback, and the third group will use VR without the neurofeedback feature.
Participants will attend 16 training sessions over eight weeks, with each session lasting about 35 to 60 minutes. Before, immediately after, and two months after the training, children will complete cognitive tests to measure their attention and memory skills. Parents and teachers will also give feedback on the children's behavior at home and school. To join the study, children must have a clinical diagnosis of ADHD and show attention problems as reported by parents or teachers. However, children with certain conditions, like Autism Spectrum Disorder, or those currently in other treatments, cannot participate. This study hopes to find helpful new ways to support children with ADHD.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children aged 7- 12
- • Clinical diagnosis of ADHD
- • Significant teacher- or parent-reported attention problems during screening
- Exclusion Criteria:
- • Inability to answer the first five questions in Raven's Progressive Matrices
- • Hearing, visual, or physical impairments that might hinder participation in the training and assessment activities
- • Clinical diagnosis and suspected cases of Autism Spectrum Disorder (ASD)
- • Prior or current participation in NFT
- • Current participation in a psychotherapeutic treatment
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Kar-man Kathy Shum, PhD
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported